These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17985997)

  • 21. ADMET modeling approaches in drug discovery.
    Ferreira LLG; Andricopulo AD
    Drug Discov Today; 2019 May; 24(5):1157-1165. PubMed ID: 30890362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors.
    Hou TJ; Xu XJ
    J Chem Inf Comput Sci; 2003; 43(6):2137-52. PubMed ID: 14632466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gaussian processes for classification: QSAR modeling of ADMET and target activity.
    Obrezanova O; Segall MD
    J Chem Inf Model; 2010 Jun; 50(6):1053-61. PubMed ID: 20433177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of a set of simple, interpretable ADMET rules of thumb.
    Gleeson MP
    J Med Chem; 2008 Feb; 51(4):817-34. PubMed ID: 18232648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-throughput and in silico techniques in drug metabolism and pharmacokinetics.
    van de Waterbeemd H
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):33-43. PubMed ID: 11865671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro methods in the prediction of kinetics of drugs: focus on drug metabolism.
    Raunio H; Taavitsainen P; Honkakoski P; Juvonen R; Pelkonen O
    Altern Lab Anim; 2004 Oct; 32(4):425-30. PubMed ID: 15651928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery.
    Khakar PS
    Curr Top Med Chem; 2010; 10(1):116-26. PubMed ID: 19929825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards Predicting the Cytochrome P450 Modulation: From QSAR to Proteochemometric Modeling.
    Shoombuatong W; Prathipati P; Prachayasittikul V; Schaduangrat N; Malik AA; Pratiwi R; Wanwimolruk S; Wikberg JES; Gleeson MP; Spjuth O; Nantasenamat C
    Curr Drug Metab; 2017 Jul; 18(6):540-555. PubMed ID: 28322159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers.
    González-Díaz H; Duardo-Sanchez A; Ubeira FM; Prado-Prado F; Pérez-Montoto LG; Concu R; Podda G; Shen B
    Curr Drug Metab; 2010 May; 11(4):379-406. PubMed ID: 20446904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 33. Open access in silico tools to predict the ADMET profiling of drug candidates.
    Kar S; Leszczynski J
    Expert Opin Drug Discov; 2020 Dec; 15(12):1473-1487. PubMed ID: 32735147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing the links between in vitro potency, ADMET and physicochemical parameters.
    Gleeson MP; Hersey A; Montanari D; Overington J
    Nat Rev Drug Discov; 2011 Mar; 10(3):197-208. PubMed ID: 21358739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Machine learning models for classification tasks related to drug safety.
    Rácz A; Bajusz D; Miranda-Quintana RA; Héberger K
    Mol Divers; 2021 Aug; 25(3):1409-1424. PubMed ID: 34110577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting permeability coefficient in ADMET evaluation by using different membranes-interaction QSAR.
    Liu J; Li Y; Pan D; Hopfinger AJ
    Int J Pharm; 2005 Nov; 304(1-2):115-23. PubMed ID: 16182478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSAR without borders.
    Muratov EN; Bajorath J; Sheridan RP; Tetko IV; Filimonov D; Poroikov V; Oprea TI; Baskin II; Varnek A; Roitberg A; Isayev O; Curtarolo S; Fourches D; Cohen Y; Aspuru-Guzik A; Winkler DA; Agrafiotis D; Cherkasov A; Tropsha A
    Chem Soc Rev; 2020 Jun; 49(11):3525-3564. PubMed ID: 32356548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties.
    Xiong G; Wu Z; Yi J; Fu L; Yang Z; Hsieh C; Yin M; Zeng X; Wu C; Lu A; Chen X; Hou T; Cao D
    Nucleic Acids Res; 2021 Jul; 49(W1):W5-W14. PubMed ID: 33893803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.